Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Rufu Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2026-0016, 0000-0003-4568-1324; OpenAlex author ID A5101607615, A5101607617. Sources: OpenAlex.

Their work

Papers
27 (first author 0, last author 19)
Trials
0
Grants
0
Labs led
2
Collaborators
57
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 4 papers · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 5 papers · 2023: 3 papers · 2024: none · 2025: 3 papers

Papers 27

  1. Life's Essential 8, genetic susceptibility, and risk of incident pancreatic cancer: A prospective cohort study. Last author DOI 10.1002/ijc.35184↗
  2. Combining genetic and non-genetic factors to predict the risk of pancreatic cancer in patients with new-onset diabetes mellitus. Last author DOI 10.1186/s12916-025-04048-4↗
  3. N4-acetylcytidine modification of ITGB5 mRNA mediated by NAT10 promotes perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-025-03362-2↗
  4. CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. Co-author DOI 10.1038/s41467-023-41861-y↗
  5. Association of genetic risk and lifestyle with pancreatic cancer and their age dependency: a large prospective cohort study in the UK Biobank. Last author DOI 10.1186/s12916-023-03202-0↗
  6. Leveraging Tumor Microenvironment Infiltration in Pancreatic Cancer to Identify Gene Signatures Related to Prognosis and Immunotherapy Response. Last author DOI 10.3390/cancers15051442↗
  7. Corrigendum to "LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9" [Canc. Lett. 410 (2017) 68-81]. Last author DOI 10.1016/j.canlet.2022.215836↗
  8. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215]. Last author DOI 10.1016/j.canlet.2022.215897↗
  9. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Co-author DOI 10.1038/s41388-022-02253-6↗
  10. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Last author DOI 10.1186/s12943-022-01501-3↗
  11. Correction: lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Last author DOI 10.1186/s12943-022-01585-x↗
  12. Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and A… Co-author DOI 10.1038/s41419-021-03574-2↗
  13. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Co-author DOI 10.18632/aging.202922↗
  14. Tumor-neuroglia interaction promotes pancreatic cancer metastasis. Co-author DOI 10.7150/thno.42440↗
  15. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41419-017-0052-1↗
  16. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41419-018-0486-0↗
  17. Anticancer effect of HOTTIP regulates human pancreatic cancer via the metabotropic glutamate receptor 1 pathway. Co-author DOI 10.3892/ol.2018.8870↗
  18. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Last author DOI 10.1016/j.canlet.2017.09.019↗
  19. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Last author DOI 10.1038/cddiscovery.2017.4↗
  20. Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy. Last author DOI 10.3892/ol.2017.5717↗
  21. The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. Last author DOI 10.1007/s13277-015-4234-0↗
  22. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-rela… Last author DOI 10.1016/j.canlet.2015.12.010↗
  23. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12967-015-0490-4↗
  24. Metabolic phenotypes in pancreatic cancer. Last author DOI 10.1371/journal.pone.0115153↗
  25. Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy. Last author DOI 10.18632/oncotarget.5150↗
  26. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Last author DOI 10.18632/oncotarget.5533↗
  27. Gastrectomy and risk of pancreatic cancer: systematic review and meta-analysis of observational studies. Co-author DOI 10.1007/s10552-012-0005-z↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quanbo Zhou · 20 shared papers, 2012–2025 · strength 1.87
  2. Shangyou Zheng · 15 shared papers, 2015–2022 · strength 1.39
  3. Zhiqiang Fu · 14 shared papers, 2015–2025 · strength 1.22
  4. Liangtang Zeng · 4 shared papers, 2023–2025 · strength 1.10
  5. Huilin Ye · 11 shared papers, 2015–2022 · strength 0.93
  6. Zhuo Kui Wu · 3 shared papers, 2023–2025 · strength 0.80
  7. Yu Zhou · 3 shared papers, 2023–2025 · strength 0.80
  8. Leyi Huang · 4 shared papers, 2020–2025 · strength 0.69
  9. Guolin Li · 7 shared papers, 2016–2022 · strength 0.67
  10. Chonghui Hu · 4 shared papers, 2021–2022 · strength 0.58
  11. Rihua He · 3 shared papers, 2022–2025 · strength 0.52
  12. Xiaohui Zhao · 8 shared papers, 2015–2022 · strength 0.51
  13. Zhihua Li · 6 shared papers, 2012–2022 · strength 0.50
  14. Lusheng Wei · 5 shared papers, 2017–2022 · strength 0.48
  15. Changhao Chen · 4 shared papers, 2017–2022 · strength 0.47
  16. Yimin Liu · 8 shared papers, 2015–2018 · strength 0.43
  17. Jiabin Yang · 2 shared papers, 2023 · strength 0.43
  18. Yingxue Wang · 6 shared papers, 2015–2018 · strength 0.32
  19. Xiang Zhang · 2 shared papers, 2021–2022 · strength 0.30
  20. Zhuo Wu · 1 shared paper, 2025 · strength 0.30
  21. Zhou Fang · 1 shared paper, 2025 · strength 0.30
  22. Hongcao Lin · 2 shared papers, 2021–2022 · strength 0.30
  23. Renpeng Xia · 2 shared papers, 2022 · strength 0.29
  24. Wenchao Gao · 6 shared papers, 2015–2016 · strength 0.27
  25. Yue Zhao · 3 shared papers, 2017–2022 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.